Document Type : Original Article


1 Biology Department, College of Science, Salahaddin University-Erbil, Erbil, Iraq

2 Department of biology, Nourdanesh institute of higher education, Meymeh, Isfahan, Iran

3 Personalized Medicine Research Center of AmitisGen, Tehran, Iran


HCV is a blood pathogen that affects approximately 180 million people worldwide. It has the ability to escape its host’s defense mechanism and is considered a resistant species. Toll-like receptors (TLRs) are a family of evolutionary receptors that have been identified by the diagnosis of pathogens as the main regulators of innate and acquired immune responses. Studies have shown that genetic changes in the TLR3 gene are associated with high susceptibility or resistance to immune and infectious diseases. In this study, the effects of the TLR3 gene single nucleotide polymorphism rs78726532 on susceptibility to HCV infections were examined. The association between this polymorphism and the risk of hepatitis C in 50 patients and 50 healthy subjects was investigated. The results revealed a significant relationship between polymorphism rs78726532 and hepatitis C infection (p = 0.002). Thus, it could have a therapeutic and predictive potential.


1. A. J. Muir, “The natural history of hepatitis C viral infection,”
Seminars in Gastrointestinal Disease, vol. 11, no. 2, pp. 54–61, 2000.
2. C.W. Shepard, L. Finelli, and M. J. Alter, “Global
epidemiology of hepatitis C virus infection,” Lancet Infectious
Diseases, vol. 5, no. 9, pp. 558–567, 2005.
3. D. Lavanchy, “The global burden of hepatitis C,” Liver
International, vol. 29, supplement 1, pp. 74–81, 2009.
4. J. G.McHutchison,E. J. Lawitz,M. L. Shiffman et al.,
“Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of
hepatitis C infection,” New England Journal of Medicine, vol.
361, no. 6, pp. 580–593, 2009.
5. E. J.Mifsud, A. C. L. Tan, andD. C. Jackson, “TLR agonists
as modulators of the innate immune response and their potential
as agents against infectious disease,” Frontiers in Immunology,
vol. 5, article 79, 2014.
6. S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition
and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
7. T. Kawai and S. Akira, “The role of pattern-recognition
receptors in innate immunity: update on toll-like receptors,”
Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010.
8. M. Matsumoto, K. Funami, H. Oshiumi, and T. Seya,
“Tolllike receptor 3: a link between toll-like receptor, interferon
and viruses,” Microbiology and Immunology, vol. 48, no. 3, pp.
147– 154, 2004.
9. M.-M. Yuan, Y.-Y. Xu, L. Chen, X.-Y. Li, J. Qin, and Y. Shen,
“TLR3 expression correlates with apoptosis, proliferation and
angiogenesis in hepatocellular carcinoma and predicts prognosis,”
BMC Cancer, vol. 15, no. 1, article 245, 2015.
10. Y.-Y. Xu, L. Chen, I.-M. Zhou, Y.-Y. Wu, and Y.-Y. Zhu,
“Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular
carcinomamodel,”MolecularMedicine Reports, vol. 8, no. 4, pp.
1037–1042, 2013.
11. Z. Guo, L. Chen, Y. Zhu et al., “Double-stranded RNA-
induced TLR3 activation inhibits angiogenesis and triggers
apoptosis of human hepatocellular carcinoma cells,” Oncology
Reports, vol. 27, no. 2, pp. 396–402, 2012.
12. Y.-T. Lin, A. Verma, and C. P.Hodgkinson, “Toll-like receptors
and human disease: lessons from single nucleotide polymorphisms,”
Current Genomics, vol. 13, no. 8, pp. 633–645, 2012.
13. M. Sironi, M. Biasin, R. Cagliani et al., “A common
polymorphism in TLR3 confers natural resistance to HIV-1 infection,”
Journal of Immunology, vol. 188, no. 2, pp. 818–823, 2012.
14. K. Huik, R. Avi, M. Pauskar et al., “Association between
TLR3 rs3775291 and resistance to HIV among highly exposed
Caucasian intravenous drug users,” Infection, Genetics and
Evolution, vol. 20, pp. 78–82, 2013.
15. A. Al-Qahtani, M. Al-Ahdal, A. Abdo et al., “Toll-like
receptor 3 polymorphism and its association with hepatitis B virus
infection in SaudiArabian patients,” Journal ofMedical Virology,
vol. 84, no. 9, pp. 1353–1359, 2012.